First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Khanh T DoLaura Quan Man ChowKaren ReckampRachel E SanbornHoward BurrisFrancisco RobertD Ross CamidgeConor E SteuerJohn H StricklerAmy WeiseJennifer M SpechtMartin GutierrezPeter HaughneyShawna HengelChristina Louise DerlethTimothy A YapPublished in: The oncologist (2021)
SGN-2FF demonstrated proof-of-mechanism and preliminary antitumor activity but was associated with thromboembolic events leading to study termination.